{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.9","value":"2011.8"},{"groupId":"OG001","spread":"21.2","value":"840.3"},{"groupId":"OG002","spread":"20.9","value":"1629.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Area under the observed concentration-time curve from the time of dosing to Day 7 calculated by log-linear trapezoidal approximation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received SEA-BCMA 1600 mg IV q2wk on Day 1 and 15 of each 28-day cycle, and dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part C: SEA-BCMA 1600mg and Dexamethasone"},{"description":"Participants received SEA-BCMA 800 mg IV q1wk on Day 1 and 15 of each 28-day cycle, and dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG001","title":"Part C: SEA-BCMA 800mg and Dexamethasone"},{"description":"Participants received SEA-BCMA 1600 mg IV q1wk on Day 1,8,15 and 22 of each 28-day cycle, and dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG002","title":"Part C: SEA-BCMA 1600 mg and Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Pre dose, 1 and 2 hour intradose, end of drug administration, 2, 6 , 24, 72, and 168 hours post end of infusion on Day 1","title":"AUC0-7 of SEA-BCMA: Part C","type":"SECONDARY","unitOfMeasure":"Day*ug/mL"}